Bio Pharma Dive

JULY 20, 2022

The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease.

Gene Editing 332

Gene Editing Gene Development Drugs 332

Bio Pharma Dive

JUNE 17, 2021

Capitalizing on investor interest in gene editing, the high-profile startup has secured one of the richest biotech initial public offerings priced this year.

Gene Editing 301

Gene Editing Gene 301

Bio Pharma Dive

MARCH 2, 2023

The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst.

Gene Editing 307

Gene Editing In-Vivo Gene Drugs 307

Pharmaceutical Technology

OCTOBER 22, 2024

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal worth $283m.

Gene Editing 244

Gene Editing Gene Development Medicine 244

Bio Pharma Dive

FEBRUARY 3, 2022

Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's.

Gene Editing 270

Gene Editing Gene Scientist 270

Pharmaceutical Technology

JANUARY 17, 2024

The US FDA has approved Vertex's CASGEVY, a gene-edited cell therapy, to treat transfusion-dependent beta thalassemia.

Gene Editing 245

Gene Editing Gene FDA Approval 245

Pharmaceutical Technology

MARCH 15, 2024

Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.

Gene Editing 244

Gene Editing Licensing Licensing Gene 244

Bio Pharma Dive

JULY 28, 2023

The company will lay off 87% of its workforce and halt further research, including for a gene editing therapy to treat the rare disease PKU.

Gene Editing 246

Gene Editing Gene Sales Research 246

Bio Pharma Dive

JULY 17, 2023

Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.

Gene Editing 237

Gene Editing Gene In-Vivo Research 237

Pharmaceutical Technology

JUNE 29, 2023

Experts warn caution around CRISPR gene editing technology on human embryos as it may have dangerous consequences.

Gene Editing 246

Gene Editing Gene 246

Bio Pharma Dive

OCTOBER 3, 2022

Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.

Gene Editing 356

Gene Editing Gene 356

Bio Pharma Dive

MARCH 2, 2022

A federal patent board ruled Broad Institute scientists were first to a key gene editing advance, weakening the patent position of Intellia and CRISPR Therapeutics, which hold licenses through the University of California.

Gene Editing 205

Gene Editing Gene Licensing Licensing 205

Bio Pharma Dive

JUNE 11, 2022

Positive data from 75 patients with either sickle cell disease or beta thalassemia keep the companies’ therapy on track to become the first CRISPR-based treatment submitted to drug regulators, possibly by the end of the year.

Gene Editing 341

Gene Editing Gene Regulation Drugs 341

Bio Pharma Dive

JANUARY 7, 2025

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

Gene Editing 301

Gene Editing Gene Research Medicine 301

Bio Pharma Dive

SEPTEMBER 29, 2021

Early study results offer some hopeful signs of efficacy, but the small number of patients treated and short follow-up limit firmer conclusions.

Gene Editing 357

Gene Editing Gene 357

Bio Pharma Dive

APRIL 25, 2024

“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.

Gene Editing 307

Gene Editing Gene Genetics Medicine 307

Bio Pharma Dive

JUNE 9, 2023

The regulator will issue separate verdicts on the pioneering treatment’s use in sickle cell disease and beta thalassemia, with the first expected late this year.

Gene Editing 326

Gene Editing Gene Regulation Drugs 326

Bio Pharma Dive

AUGUST 7, 2020

Development of EDIT-101, the first CRISPR-based therapy to be used in a company-led trial to alter genes within a person's body, will now move forward under Editas' sole ownership.

Gene Editing 337

Gene Editing Gene Trials Development 337

Bio Pharma Dive

DECEMBER 8, 2023

In addition to clearing Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, the FDA also granted an early OK to Bluebird bio’s sickle cell treatment Lyfgenia.

Gene Editing 349

Gene Editing Gene 349

Bio Pharma Dive

NOVEMBER 20, 2020

Through a deal with Precision Biosciences, the pharma aims to develop therapies for genetic disorders, including Duchenne muscular dystrophy.

Gene Editing 261

Gene Editing Gene Genetics Development 261

Bio Pharma Dive

APRIL 3, 2023

The approval application is the first in the U.S. for a CRISPR-based medicine and puts the partners ahead of a rival therapy from Bluebird bio.

Gene Editing 313

Gene Editing Gene Medicine Drugs 313

Bio Pharma Dive

JUNE 15, 2023

Lilly will pay the genetic medicine specialist $60 million upfront to work together on a treatment targeting a risk factor known as Lp(a).

Gene Editing 322

Gene Editing Gene Genetics Medicine 322

Worldwide Clinical Trials

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow.

Gene Editing 189

Gene Editing Gene Gene Therapy In-Vivo 189

Bio Pharma Dive

FEBRUARY 22, 2023

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

Gene Editing 261

Gene Editing Gene In-Vivo RNA 261

Bio Pharma Dive

DECEMBER 5, 2020

Results from 10 patients with beta thalassemia or sickle cell disease show CRISPR Therapeutics and Vertex's pioneering treatment to be effective, building on earlier study data.

Gene Editing 339

Gene Editing Gene 339

Bio Pharma Dive

NOVEMBER 30, 2022

The company, which draws on research by Jim Wilson’s lab at UPenn, says the $65 million it raised will support the start of human testing of its lead drug through to initial clinical data.

Gene Editing 303

Gene Editing Gene Drugs Research 303

Bio Pharma Dive

FEBRUARY 10, 2021

Using technology from Caribou Biosciences, AbbVie hopes to engineer "off-the-shelf" CAR-T cells that can better withstand attacks from the immune system.

Gene Editing 301

Gene Editing Gene Engineer 301

Pharmaceutical Technology

MARCH 19, 2025

for its gene editing therapeutic pipeline aimed at liver and central nervous system diseases. Arbor Biotechnologies has closed $73.9m

Gene Editing 147

Gene Editing Gene 147

Bio Pharma Dive

MAY 2, 2024

Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.

Gene Editing 157

Gene Editing Gene Research 157

Bio Pharma Dive

JANUARY 12, 2021

Verve, a buzzy gene editing startup, unveiled its first drug candidate on Tuesday, while Eli Lilly's and Pfizer's CEO gave updates on Alzheimer's and dealmaking.

Gene Editing 189

Gene Editing Gene Drugs 189

Bio Pharma Dive

JULY 14, 2021

Formed around research from the Broad Institute's David Liu and Andrew Anzalone, Prime has attracted significant funding from a wide range of high-profile biotech backers.

Gene Editing 313

Gene Editing Medicine Gene Research 313

Bio Pharma Dive

JUNE 21, 2021

The next six months could feature clinical milestones for CRISPR gene editing, the treatment of COVID-19, microbiome drugs and gene-targeted cancer therapy.

Gene Editing 363

Gene Editing Clinical Trials Clinical Trials Gene 363

Bio Pharma Dive

NOVEMBER 15, 2023

Since halting work on a sickle cell treatment early this year, Graphite Bio has laid off staff, shed assets and, now, agreed to be subsumed via a merger with Lenz Therapeutics.

Gene Editing 273

Gene Editing Gene 273

Bio Pharma Dive

JANUARY 4, 2024

Moonwalk Biosciences, the latest biotech cofounded by the gene editing scientist, joins other startups aiming to alter gene expression without changing DNA.

Gene Editing 351

Gene Editing Gene Expression DNA Gene 351

Bio Pharma Dive

NOVEMBER 7, 2022

Verve didn’t say what led to the FDA’s decision, but claimed it hasn’t observed any safety issues in an ongoing trial in New Zealand and the U.K, where enrollment will continue.

Gene Editing 319

Gene Editing Gene Trials 319

Bio Pharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Gene Editing 293

Gene Editing Insulin Gene Licensing 293

Bio Pharma Dive

OCTOBER 20, 2022

The gene editing startup is one of less than two dozen biotech companies to debut on Wall Street this year, as the pace of IPOs remains far off last year’s trajectory.

Gene Editing 356

Gene Editing Medicine Gene 356